Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 4;16(2):38-42.
doi: 10.1002/cld.964. eCollection 2020 Aug.

Thinking Outside of Urso

Aaron Hakim  1 , Vilas Patwardhan  1 , Alan Bonder  1
Affiliations
Review

Thinking Outside of Urso

Aaron Hakim et al. Clin Liver Dis (Hoboken). .
No abstract available

PubMed Disclaimer

Figures

Fig 1
Fig 1
Reaching a confirmed diagnosis of PBC.
Fig 2
Fig 2
Stepwise approach to the management of PBC. *Dose adjust in Child‐Pugh class B/C cirrhosis.
Fig 3
Fig 3
Schematic of PBC pathogenesis and potential targets for therapeutic intervention.
Fig 4
Fig 4
Mechanism of action for existing and emerging therapies in PBC.
See this image and copyright information in PMC

References

    1. Harms MH, van Buuren HR, Corpechot C, et al. Ursodeoxycholic acid therapy and liver transplant‐free survival in patients with primary biliary cholangitis. J Hepatol 2019;71:357‐365. - PubMed
    1. ter Borg PC, Schalm SW, Hansen BE, et al. Prognosis of ursodeoxycholic acid‐treated patients with primary biliary cirrhosis. Results of a 10‐yr cohort study involving 297 patients. Am J Gastroenterol 2006;101:2044‐2050. - PubMed
    1. Lammers WJ, van Buuren HR, Hirschfield GM et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow‐up study. Gastroenterology 2014;147:1338‐1349.e5; quiz e15. - PubMed
    1. Nevens F, Andreone P, Mazzella G, et al. A placebo‐controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016;375:631‐643. - PubMed
    1. Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha‐ethyl‐chenodeoxycholic acid (6‐ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002;45:3569‐3572. - PubMed